Genprex signs CDMO deal to scale up manufacturing for diabetes gene therapy program - GNPX News | RalliesGenprex signs CDMO deal to scale up manufacturing for diabetes gene therapy program
G
GNPX• CDMO agreement expands diabetes gene therapy manufacturing
- Genprex signed a development and manufacturing agreement with a U.S.-based CDMO to scale up its diabetes gene therapy manufacturing.
- Work shifts the AAV-based program from research-grade output to cGMP production for IND-enabling preclinical studies.
- The CDMO is expected to supply drug product for future clinical trials as Genprex advances the candidate toward clinical evaluation.
